Company / Accounts Receivable
Bioventus Inc. Accounts Receivable History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$128.3M
FY2025
5-year range
$122.8M / $136.3M
FY2021-FY2025
Trend
+0.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $123M to $128M over the past 2 years.
Based on SEC 10-K filings.
$128M in FY2025 with a 3-year CAGR of -2.0%.
Improved from $123M to $128M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -2.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -2.0%, indicating a declining trend.
- In FY2025, accounts receivable increased 0.7% year-over-year.
- Peak accounts receivable was recorded in FY2022.
- Lowest accounts receivable in the period was in FY2023.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.93 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $128.3M | +0.7% |
| FY2024 | $127.4M | +3.7% |
| FY2023 | $122.8M | -9.9% |
| FY2022 | $136.3M | +9.1% |
| FY2021 | $125.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026